• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 23: Pricing Model for Fair Value of Category B Assets in Z (Phase-2 Valuation Event) based on “interaction-type” and “prompt grid” Method

Part 23: Pricing Model for Fair Value of Category B Assets in Z (Phase-2 Valuation Event) based on “interaction-type” and “prompt grid” Method

COM Part 23:

Pricing Model for Category B Assets in Z (Phase-2 Valuation Event).

  • Launched on 9/17/2026 as the 1st First LPBI model that prices Z by interaction type + prompts
  • A Pricing Model for arriving at one Z
  • Prompts specify operations on the pair of coordinates in a Matrix [a COM Part(s) or e-Series Volume(s)] AND a member of Category B Assets [EXT-C.1, EXT-C.2, EXT-C.3 (C.3.1–C.3.4), EXT-C.6, EXT-C.7, EXT-C.8, EXT-C.9 (C.9.1–C.9.11), and EXT-C.10 (the website).]

This Pricing Model for Intellectual PROPERTIES embedding Artificial Intelligence Agentic Functions and Model Components being Prompts to Agents derives thr formulation of Prompts and their relative weights from Types of Interactions between Composition of Methods Parts and Trainable Data Sets in the Group of Category B Assets. Performed with Expert Humans involvement.

  • In Each Cell that Grok had identified and had classified an Interaction by Type and color marked on the Grid in a Password Protect Page nested to this Page. This Page shows for Public Access all interactions declared, their identify is found in the nexted page.
  • a List of 5 Prompts appropriate to Interaction Type will command Compute operation(s) on Training Data Set in the two coordinates of COM Part(s) / e-Series Volume(s) and Category B Assets.
  • Prompts as the model component. The five prompts per classified cell are the agentic payload: they tell an agent what compute to run on that pair. That is IP-shaped (prompt library + interaction type + named asset). It is closer to a Tool Factory extension than to a spreadsheet of made-up millions.
  • COM 23 is strong as a governance and agentic pricing method.
  • The Type of Interactions include:
  1. CTS=Core Training Substrate |
  2. MI=Methodology Input |
  3. IE=Infrastructure Enabler |
  4. MP=Monetization/Packaging |
  5. AE=Augmentation/Evolution |
  6. IF=Indirect/Foundational |
  7. SI=System Integration.

Blank=no classified interaction.

EXT-C.10 column selective — 13 of 22 COM Parts; 6 e-Series IF; 19 marks in the column (hosting is IE; not every COM part, Nine COM Parts correctly stay blank (3, 6, 7, 8, 10, 11, 12, 17, 20). The 6 e-Series × EXT-C.10 marks (hosting / IF only)
Series A Vol 4 · Series A Vol 6 · Series B Vol 1 & 2 · Series C Vol 1 & 2 · Series D Vol 2 & 3 · Series E Vol 4.

Fence

COM 23 supports one Z (Phase-2).

  • Chart 4 stays $650 M.
  • Five production prompts = post-T1; not in this file.

Merit for Z (Phase-2), if used this way

  1. Filter. Only classified cells enter the Z memo. Blank = no claim.
  2. Weight, not price. Types can be weights (CTS and SI heavier than IF) inside one Z. They must not become 400 mini-invoices.
  3. No double count. COM Part 13 sits in Appendix C-22, Part A, Chart 1 (inserted 16 Aug 2026). COM Part 21 sits in Appendix C-22, Part B, Chart 2 (inserted 16 Aug 2026). Those columns in COM 23 are pairing only.
  4. One Z still one Z. EXT-C.3.2 and EXT-C.3.3 stay inside Z if Schedule B = Yes; newsletters ≠ ROFR ≠ compute PO.
  5. COM 23 itself. Treat COM Part 23 as Category B method IP (with COM 18–20 / COM 22 methods), title at T1, value inside one Z — unless the Board later votes a Phase-1 number, which it has not.

 

List of COM Parts include:

1 Curation
2 IT SOP
3 MFMH protocols
4 Valuation model
5 Workflows
6 Image types
7 KDP royalties
8 Class III views
9 Scoop.it
10 EI methods
11 Validation
12 Monetization schedules
13 15 SLM sets
14 AJAUS
15 Ontology
16 Agentic + chain EI
17 B2C payments
18 Agentic / multimodal
19 Orbital compute
20 Next-gen token
21 Yields Outcomes
22 Proprietary MFMH + API

This is the List of All e-Series Volume(s) involved in Pairing with a member of Category B Assets:

PAIRING WITH e-Series Volume(s): “Combining with …” Series A, Volume 4
PAIRING WITH e-Series Volume(s): “Combining with …” Series A, Volume 6
PAIRING WITH e-Series Volume(s): “Combining with …” Series B, Volumes  1 & 2
PAIRING WITH e-Series Volume(s): “Combining with …” Series C, Volumes  1 & 2
PAIRING WITH e-Series Volume(s): “Combining with …” Series D, Volumes  2 & 3
PAIRING WITH e-Series Volume(s): “Combining with …” Series E, Volume  4

 

List of Category B Assets:

Appendix EXT-C – Category B Assets: Due Diligence Tools, New COM Parts Priced in Phase-1, New COM Parts in Z, Trainable Data Sets: Pre-2026 (C.3.1 & C.3.4) & Trainable Data Sets: Post-2026 (C.3.2 & C.3.3)

AND

Appendix EXT-C: EXT-C.9, Group 1: “Combined with …” COM Part(s)

AND

Appendix EXT-C: EXT-C.9, Group 2: Portals “Combined with …” e-Series Volume(s)

AND

EXT-C.10 Website / 52 Pages (Category B, in Z)

Four Boards of COM and Category B Assets

For Technical Aspect of the Development of the PRICING Tool See sub page

COM – Part 23: Technical Knowledge Depth Layer – Architecture and Source Materials for A Pricing Model based on “interaction-type” and “prompt grid” Method for Fair Value of Category B Assets in Z

https://pharmaceuticalintelligence.com/2026-beyond-master-plan/composition-of-methods-com/part-23-pricing-model-for-fair-value-of-category-b-assets-in-z-phase-2-valuation-event-based-on-interaction-type-and-prompt-grid-method/com-part-23-technical-knowledge-depth-layer-architecture-source-materials-for-a-pricing-model-based-on-interaction-type-and-prompt-grid-method-for-fair-v/

 

 

 

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • COM – Part 23: Technical Knowledge Depth Layer – Architecture & Source Materials for A Pricing Model based on “interaction-type” and “prompt grid” Method for Fair Value of Category B Assets in Z

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
    • FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d